Our Senior Team

Dr Michael O’Neill

(United Kingdom)

  • Dr Michael O’Neill has extensive experience in the pharmaceutical industry, having worked for Merck Sharpe and Dohme, Laboratorios Almirall, Eli Lilly and Eolas Biosciences.
  • In addition to the UK, Michael has worked in Spain in the areas of pain, psychiatric and neurological disorders and was involved in setting up of a neuroscience lab there.
  • At Eli Lilly, UK he worked on a broad range of projects targeting CNS disorders and was responsible for project and portfolio management.
  • Michael was responsible for the Novel Targets portfolio for Eli Lilly bringing forward new projects into the pipeline.
  • He gained significant expertise in the evaluation, structuring and delivering of projects to key milestones, up to and including early clinical development.
  • Michael is an accomplished research leader with extensive program and portfolio management experience having lead specialist and multidisciplinary teams in UK, Europe and in the US.
  • Michael also worked closely with marketing and medical divisions within Lilly to provide support for marketed products such as Cymbalta and Zyprexa.
  • As a consultant Michael has helped companies and organisations gain funding or major partnerships, progress projects and reviewed their operations.
  • Michael has authored over 80 papers, book chapters, patents and abstracts.
  • He has held an adjunct appointment at the University of Leeds and supervised PhD students at Nottingham, Oxford and Sussex Universities.
  • Michael also held an Honorary Visiting Senior Lecturership at the Institute of Psychiatry, London and an Honorary Visiting Lecturership at the Science Policy Research Unit at the University of Sussex.
  • Michael also has a Diploma in Executive Coaching and Organizational Development.
  • He is an expert on BioMedical Research and has worked on a number of compounds currently in late stage development.
  • He specializes in Innovation and has extensive interest and experience in Education and Communication.
  • Michael has been involved with numerous consultancy assignments for companies from start ups to Fortune  500 pharma.


<< Back to The Team